Needham & Company Gives Buy Rating to Medidata Solutions (MDSO)
Medidata Solutions traded down 2.46% on Wednesday, hitting $27.70. Medidata Solutions has a 1-year low of $14.07 and a 1-year high of $29.65. The company has a market cap of $662.8 million and a price-to-earnings ratio of 17.75.
The company last announced its quarterly results on Tuesday, May 1st. It reported $0.26 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of $0.22 EPS by $0.04. The company’s quarterly revenue was up 23.5% on a year-over-year basis. Analysts expect that Medidata Solutions will post $0.32 EPS next quarter.
Other equities research analysts have also recently issued reports about the stock. Analysts at Jefferies Group (NYSE: JEF) raised their price target on shares of Medidata Solutions from $31.00 to $34.00 in a research note to investors on Wednesday. Separately, analysts at Raymond James (NYSE: RJF) upgraded shares of Medidata Solutions from a “market perform” rating to an “outperform” rating in a research note to investors on Friday, April 20th.
Medidata Solutions, Inc. (Medidata) is a provider of hosted clinical development solutions. The Company’s customers include pharmaceutical, biotechnology and medical device companies, academic institutions, contract research organizations (CROs), and other organizations engaged in clinical trials.